Aquestive Therapeutics reported a significant revenue decline and wider EBITDA loss for Q3 2026, missing expectations. The company maintained full-year guidance and highlighted a key PDUFA goal date for its Anaphylm product in March 2027, which could be a future catalyst despite the current financial underperformance.
Aquestive Therapeutics reported a substantial 40% year-over-year decline in Q3 2026 revenues, primarily due to fluctuations in Suboxone product orders, and a wider non-GAAP adjusted EBITDA loss. This financial underperformance is a negative short-term indicator for the company. However, the maintenance of full-year guidance and the upcoming PDUFA goal date for Anaphylm in March 2027 present a potential long-term opportunity. Traders should note the immediate negative financial results but also consider the future catalyst of Anaphylm's regulatory decision, which could significantly impact the stock's trajectory.